MH
Therapeutic Areas
Biohaven Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BHV-7000 (Kv7.2/3 opener) | Focal Epilepsy | Phase 2 |
| Taldefgrobep alfa | Spinal Muscular Atrophy (SMA) | Phase 3 |
| BHV-1300 (IgE degrader) | Immunoglobulin Light-chain (AL) Amyloidosis | Phase 1/2 |
| BHV-1200 (BCMA degrader) | Multiple Myeloma | Phase 1 |
| BHV-2100 (mGluR2/3 NAM) | Treatment-Resistant Depression (TRD) | Phase 1 |
| BHV-5000 (NMDA antagonist) | Major Depressive Disorder (MDD) | Phase 1 |
| BHV-6000 (IRE1α inhibitor) | Neurodegeneration | Preclinical |
| BHV-1100 (IgG degrader) | Autoimmune Diseases | Preclinical |
Leadership Team at Biohaven
VC
Vlad Coric, M.D.
Chief Executive Officer
BL
Bruce Leuchter, M.D.
Chief Financial Officer
IA
Irina Antonijevic, M.D., Ph.D.
Chief Medical Officer
JR
John R. Whitaker, J.D.
Chief Legal Officer and Corporate Secretary
MB
Matthew Buten, Ph.D.
Chief Innovation Officer
RB
Robert Berman, M.D.
Chief Strategy Officer and Head of R&D
JE
James Engelhart, CPA
Chief Accounting Officer
GB
Gregory Bailey, M.D.
Chairman of the Board of Directors
JP
Julia P. Gregory
Board Director
JW
John W. Childs
Board Director